Results 301 to 310 of about 382,920 (355)
Some of the next articles are maybe not open access.
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.
The Journal of the National Comprehensive Cancer Network, 2022The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma.
Natalie S. Callander +28 more
semanticscholar +1 more source
Plasma cell myeloma with D-myeloma protein (IgD myeloma)
The American Journal of Medicine, 1968Abstract Plasma cell myeloma distinguished by a serum D-myeloma protein has been found in many parts of the world and more than two dozen cases have been identified. Noteworthy observations are the high frequency (80 per cent) of D-myeloma protein with lambda-light chains (D-myeloma protein—type L) and the almost invariable presence of Bence Jones ...
J L, Fahey +3 more
openaire +2 more sources
The Lancet Haematology, 2022
BACKGROUND Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence cases leukaemia, lymphoma, and multiple myeloma in 2020. Identifying its geographical distribution, risk factors, and epidemiological trends could help identify high-risk ...
Junjie Huang +9 more
semanticscholar +1 more source
BACKGROUND Multiple myeloma accounted for 176 404 (14%) of 1 278 362 the incidence cases leukaemia, lymphoma, and multiple myeloma in 2020. Identifying its geographical distribution, risk factors, and epidemiological trends could help identify high-risk ...
Junjie Huang +9 more
semanticscholar +1 more source
The Lancet Oncology, 2019
BACKGROUND Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma.
S. Lonial +37 more
semanticscholar +1 more source
BACKGROUND Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma.
S. Lonial +37 more
semanticscholar +1 more source
Disease-a-Month, 1990
Myeloma is a malignancy of plasma cells that are terminally differentiated B-lymphocytes. The clinical spectrum varies from the incidental discovery of a pathologically raised monoclonal immunoglobulin on routine electrophoresis in asymptomatic patients to widespread skeletal involvement with incapacitating bone pain.
openaire +2 more sources
Myeloma is a malignancy of plasma cells that are terminally differentiated B-lymphocytes. The clinical spectrum varies from the incidental discovery of a pathologically raised monoclonal immunoglobulin on routine electrophoresis in asymptomatic patients to widespread skeletal involvement with incapacitating bone pain.
openaire +2 more sources
Current Opinion in Oncology, 1994
The mortality associated with multiple myeloma is due to the progressive accumulation of a clonal population of plasma cells in the bone marrow. Tumor cells may also be found in the blood and other extramedullary sites, especially in the terminal stages of the disease.
M V, Seiden, K C, Anderson
openaire +2 more sources
The mortality associated with multiple myeloma is due to the progressive accumulation of a clonal population of plasma cells in the bone marrow. Tumor cells may also be found in the blood and other extramedullary sites, especially in the terminal stages of the disease.
M V, Seiden, K C, Anderson
openaire +2 more sources
The Lancet Haematology, 2022
Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease,
N. Raje +35 more
semanticscholar +1 more source
Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and host-related factors. Given that infectious risk is cumulative through the course of the disease,
N. Raje +35 more
semanticscholar +1 more source
Hematology/Oncology Clinics of North America, 2014
Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes.
Sarah A, Holstein +2 more
openaire +2 more sources
Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes.
Sarah A, Holstein +2 more
openaire +2 more sources
The Lancet, 2019
BACKGROUND Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action.
M. Attal +115 more
semanticscholar +1 more source
BACKGROUND Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action.
M. Attal +115 more
semanticscholar +1 more source
The Lancet, 2020
BACKGROUND Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma.
M. Dimopoulos +10 more
semanticscholar +1 more source
BACKGROUND Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma.
M. Dimopoulos +10 more
semanticscholar +1 more source